As families prepare for the new school year, CooperVision is urging parents to make children’s eye health a back-to-school priority through a nationwide myopia awareness campaign, new educational resources through The Myopia Collective, and limited-time rebates on eligible products. These initiatives are designed to meet caregivers and eye care professionals (ECPs) where they are—online, in-office, and in the community—delivering timely education, practical tools, and meaningful support during one of the most critical moments in a child’s vision journey.
“The back-to-school season is an exciting time for kids and parents alike, filled with fresh starts, new routines, and big expectations,” said Michele Andrews, OD, Vice President, Marketing and Professional Affairs, Americas, CooperVision. “Clear vision plays a vital role in a child’s ability to learn and thrive in the classroom, yet it’s often overlooked.1,2 We want to make it easier for families and ECPs to take action.”
“MiSight Today. Anything Tomorrow.” Campaign Empowers Parents
Continuing its leadership in myopia management, CooperVision launched its fifth consecutive advocacy initiative, “MiSight Today. Anything Tomorrow.” The campaign is designed to empower parents with the knowledge and tools to not only correct their child’s myopia, but also take steps to help slow its progression with MiSight 1 day,†‡3,4 the first and only FDA-approved* soft contact lens proven to slow the progression of myopia in children, aged 8-12 at the initiation of treatment.§3 The effort emphasizes the importance of scheduling a comprehensive eye exam before the school year begins, and is backed by strategic media investments and content partnerships in key markets.
In addition, The Myopia Collective—CooperVision’s education and advocacy initiative developed in partnership with the American Optometric Association—has expanded its free resources for ECPs. New materials include educational tools for children and parents, in-practice communication aids, and a Myopia Fact Sheet now translated into multiple languages to help reach even more families.
To provide further support this time of year, CooperVision is offering limited-time rebates on a range of eligible products. These offers are designed to make it easier for parents to prioritize their children’s vision care and ensure they start the school year seeing clearly.
“We’re committed to supporting parents and ECPs with the resources they need, not just during the back-to-school season, but all year long. Together, we can help more kids see the world clearly today and protect their eyesight for the future,” *†‡3,4 said Dr. Andrews.
To learn more, visit www.CooperVision.com.
###
* Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† ActivControl technology in MiSight 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.
‡MiSight 1 day shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.
§Compared to a single vision 1 day lens over a 3 year period.
1. E. L. Lamoureux, J. Wang, T. Aung, S. M. Saw, T. Y. Wong; Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). Invest. Ophthalmol. Vis. Sci. 2008;49(13):4469.
2. Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore.
3. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
4. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
